Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-28T10:15:09.156Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of plasma levels of BDNF in patients with disorder depressive

Published online by Cambridge University Press:  13 August 2021

D. Galletta ,
C. Mazzarino ,
G. Cusumano  and
A. Santoro
D. Galletta*
Affiliation:
Department Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, Italy
C. Mazzarino
Affiliation:
Department Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, Italy
G. Cusumano
Affiliation:
Department Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, Italy
A. Santoro
Affiliation:
Department Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

According to the World Health Organization (WHO, 2017) depressive disorder continues to be the most widespread and growing mental illness in the world, also assumes that in 2020 depression will have a prevalence equal to one in six individuals. Studies of neuroanatomy have highlighted structural alterations in the hippocampus, striatal nuclei and prefrontal cortex in patients with mood disorders. This alteration in depressed patients is closely related to the secretion of neurotrophic factors, in particular there is a reduction in BDNF (Brain Derived Neurotrophic Factor).

Objectives

The objective of this study is to demonstrate which treatments are effective in reducing depressive symptoms that allow the increase of BDNF and consequently the structural homostaticity of the brain.

Methods

We have selected data from the literature of the last decade, collected on major search engines such as: Google Scholar, Research Gate, PubMed, Ebsco. Articles collected by selecting the following Keyword: depression, BDNF (Brain Derived Neurotrophic Factor), neuroimaging cognitive behavior therapy.

Results

The results show that in patients treated with a single drug treatment or vagus nerve stimulation, repetitive transcranial magnetic stimulation (Lang et al., 2008) or electroconvulsive therapy had improvements in BDNF levels, although compared to drug treatment there are problems of no responders, no compliance and lack of effectiveness in reducing vulnerability to relapse. In addition, the study has shown that patients treated with cognitive behavioral therapy have reported greater changes in the frontal and temporal cortex reducing both depressive symptoms and the risk of relapse.

Conclusions

Underlines the importance of an integrated approach

Keywords

Depressive Disorderplasma levelBDNF
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S335
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.